What is Verastem, Inc. (VSTM) stock price today?

Verastem, Inc. (VSTM) is currently trading at $8.38, up 3.33% today.

What is VSTM P/E ratio?

Verastem, Inc.'s P/E ratio is -3.13. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is VSTM return on equity (ROE)?

Verastem, Inc.'s return on equity (ROE) is -467.49%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Verastem, Inc.'s market cap?

Verastem, Inc. has a market capitalization of $736.38M.

NASDAQ · Biotechnology

Verastem, Inc. (VSTM) Stock

$8.38 +3.33% NASDAQ: VSTM Healthcare

Valuation

Metric	Value
Price	$8.38
Market Cap	$736.38M
P/E Ratio	-3.13
P/B Ratio	15.42
P/S Ratio	7.73
EPS (TTM)	$-3.02
52-Week High	$10.82
52-Week Low	$3.43
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-467.49%
ROA	-98.15%
ROCE	-124.47%
Gross Margin	-548.39%
Operating Margin	-548.39%
Net Margin	-231.59%
Debt/Equity	1.69
Current Ratio	3.10

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$2.0M	$3.0M	$0	$10.0M	$31.0M
Operating Profit	$-61.0M	$-73.0M	$-92.0M	$-115.0M	$-170.0M
Net Profit	$-71.0M	$-74.0M	$-87.0M	$-131.0M	$-209.0M
EPS	$-4.92	$-4.57	$-3.96	$-3.66	$-3.02
Op Margin	-2991.2%	-2809.6%	—	-1149.6%	-550.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$109.0M	$95.0M	$150.0M	$102.0M	$246.0M
Total Liabilities	$21.0M	$48.0M	$92.0M	$130.0M	$189.0M
Cash	$21.0M	$75.0M	$78.0M	$89.0M	$205.0M
Borrowings	$3.0M	$27.0M	$42.0M	$42.0M	$77.0M

Latest News

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer Business Wire · Jul 22, 2026 RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) Insider Monkey · Jul 15, 2026 Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? Zacks · Jul 10, 2026 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT Newswires · Jul 7, 2026 Here’s What RBC Capital Has to Say About Verastem (VSTM) Insider Monkey · Jul 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-54.0M	$-64.0M	$-86.0M	$-105.0M	$-138.0M
Investing Cash Flow	$0	$66.0M	$-44.0M	$60.0M	$-10.0M
Financing Cash Flow	$0	$0	$0	$41.0M	$0
Net Cash Flow	$-47.0M	$54.0M	$3.0M	$10.0M	$116.0M
Free Cash Flow	$-54.0M	$-64.0M	$-86.0M	$-105.0M	$-138.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.13
EV / EBITDA	-3.13
FCF Yield	-24.17%
Quick Ratio	2.22
Interest Coverage	-108.26
Return 1Y	15.51%
Return 3Y	-36.02%
Return 5Y	-86.32%

Ownership

Insiders Held0.93%

Institutions Held98.34%

Institutions Float Held99.26%

Institutional Holder	Shares	Report Date
RTW Investments LP	6,576,306	2026-03-31
Blackrock Inc.	6,194,925	2026-03-31
Deep Track Capital, Lp	5,740,850	2026-03-31
Armistice Capital, LLC	4,592,000	2026-03-31
Nantahala Capital Management, LLC	3,584,820	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACRVAcrivon Therapeutics, Inc.	$1.91	+2.14%	-1.12	$81.75M	0.00%
ANLAdlai Nortye Ltd.	$13.26	+2.00%	-8.19	$703.84M	0.00%
BBOTBridgeBio Oncology Therapeutics, Inc.	$3.31	-3.22%	-0.90	$265.15M	0.00%
CCCCC4 Therapeutics, Inc.	$3.16	+10.88%	-2.95	$349.39M	0.00%
CRDFCardiff Oncology, Inc.	$1.08	+1.89%	-1.87	$83.24M	0.00%

About Verastem, Inc.

Verastem, Inc. is led by CEO Daniel W. Paterson, employs 78 people, headquartered in US, publicly traded since 2012.

Verastem, Inc. (VSTM) stock trades at $8.38 with a market capitalization of $736.38M. The stock is valued at a price-to-earnings (P/E) ratio of -3.13, price-to-book of 15.42, price-to-sales of 7.73. Over the past 52 weeks the stock has ranged between $3.43 and $10.82, and currently trades 22.6% below its 52-week high.

On profitability, Verastem, Inc. generates a return on equity (ROE) of -467.49%, return on capital employed of -124.47%, an operating margin of -548.39%, a net profit margin of -231.59%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides